Context: Data on bone mineral density (BMD) are lacking in adults with childhood onset (CO)-craniopharyngioma (CP) with hypothalamic damage from the tumor. In patients with CO GH deficiency, BMD increases during GH treatment. Objective: The aims were to evaluate BMD in adults with CO-CPs on complete hormone replacement, including long-term GH and to evaluate the impact of hypothalamic damage on these measures. Design and participants: BMD (dual-energy X-ray absorptiometry), markers of bone turn over, physical activity and calcium intake were assessed in 39 CO-CP adults (20 women), with a median age of 28 (17-57) years, in comparison with matched population controls. Results: Late puberty induction was recorded in both genders, but reduced androgen levels in females only. Only CP women had lower BMD (PZ0.03) at L2-L4, and reduced Z-scores at femoral neck (PZ0.004) and L2-L4 (PZ0.004). Both genders had increased serum leptin levels (PZ0.001), which significantly correlated negatively with BMD at L2-L4 (PZ0.003; rZK0.5) and 45% of CP women had Z-score levels %K2.0 S.D. Furthermore, 75% of those with a Z-score %K2.0 S.D. had hypothalamic involvement by the tumor. Calcium intake (PZ0.008) and physical activity (PZ0.007) levels were reduced in CP men only. Levels of ostecalcin and crossLaps were increased in CP men only. Conclusions: Despite continuous GH therapy, low BMD was recorded in CO-CP females. Insufficient estrogen and androgen supplementation during adolescence was the main cause, but hypothalamic involvement with consequent leptin resistance was also strongly associated with low BMD in both genders.
Introduction
Craniopharyngioma (CP) is the most common tumor affecting the hypothalamic-pituitary region in children and about 50% suffer from obesity in childhood (1) . Treatment may be achieved using either primary aggressive surgery, which may increase the risk of hypothalamic, neurological, endocrine, and visual damage (2) or with conservative surgery followed by cranial radiotherapy, as an effective means to prevent recurrences (3) . Weight gain in a CP is a model for hypothalamic obesity, which develops rapidly after surgical treatment and is followed by stabilization with no regression afterwards (4) . Overweight seems to be protective against low bone mineral density (BMD) in healthy subjects (5) , possibly by the action of increased leptin levels (6) . However, in obese CP patients with hypothalamic damage, leptin levels were shown to be higher in relation to body mass index (BMI), indicating leptin resistance (7) , and among adolescents, leptin resistance was shown to be negatively correlated with BMD (8) . Presently, there is only one single study investigating BMD in CP children (9) and this was with the use of volumetric BMD (vBMD), showing a lower radial Z-score, which was most obvious in lean male CP patients. In contrast, female gender and severe obesity seemed to be protective against low vBMD in childhood (9) . Thus, BMD is not definitively settled in this population and studies in adults with hypothalamic damage are missing. Furthermore, smoking, insufficient physical activity and calcium intake, sex steroid deficiency, and female gender also tend to decrease BMD (10) .
In adults with childhood onset (CO) GH deficiency (GHD), BMD is often reduced compared with healthy controls (11, 12) , and a discontinuation of GH therapy at final height and before achievement of peak bone mass (11) is a possible contributing factor. Whether continuous GH therapy in CO GHD will result in a normalization of BMD is currently unknown. What speaks against this statement is the fact that CO GHD women suffered from a doubled incidence of nonosteoporotic fractures, in spite of continuous GH therapy (13) . Other hormones of importance for bone growth are insulin, thyroid hormones, glucocorticoids, and sex steroids, all probably acting through insulin-like growth factor 1 (IGF1) (14) .
One aim of the present study was to investigate whether BMD and bone mineral content (BMC) differed between adults with CO-CP on complete hormone replacement, including GH therapy, and matched population controls. Another aim was to evaluate the impact of tumor growth into the hypothalamus on these measurers.
Subjects and methods

Patients
Study participants were 39 (20 women) patients, aged R17 years, and recruited from 53 eligible subjects from the South Medical Region of Sweden (population 2.5 million). The patients were surgically treated for a CO-CP, between years 1958 and 2000 and alive at the date of this study. Excluded subjects (nZ14) were either assessed as unsuitable for participation by their respective physician (in dialysis, nZ1, family reasons, nZ1), or too ill/tired (nZ4), too busy (nZ4), no reason given (nZ1), or weighing O130 kg, which is the dualenergy X-ray absorptiometry (DXA)-limit (nZ3; all males). The median age at first operation was 12 years in women (range 3-20 years) and in men (3-22 years) and age at this study was 28 (18-57) years in women and 29 (17-57) years in men. Panhypopituitarism was present in 32 patients, out of which all but six patients had anti-diuretic hormone deficiency. Levothyroxine (L-T 4 ) doses were 150 (30-200) mg in men and 150 ) mg in women and hydrocortisone doses were 22 (10-50) mg in men and 16 (4-45) mg in women. Five patients (two women) with a BMI of 35 (21-38) kg/m 2 had 35-50 mg hydrocortisone daily. Twenty of the patients had received cranial radiotherapy with a median dose of 50 Gy (range 35-55 Gy) and three patients had received additional Yttrium installation. The majority (74%) of patients had one single operation. An highly experienced neurosurgeon graded the tumor location based on the operation records, and 22 (56%) of the patients had tumor growth into the third ventricle of the hypothalamus.
Seven women had menarche at 12 (10) (11) (12) (13) (14) years, but five of them had amenorrhea periods from 1 ⁄ 2 to 3 years thereafter. The remaining 13 women had puberty induction at 15 (12-18) years of age. Time since operation to start of sex steroid substitution was 2 (0-14) years and all females were substituted with estrogens 1-2 mg/day throughout the follow-up. At the time of this study, 85% were on oral sex steroid replacement; 14 received combinations of oral gestagens and estrogens, of them 11 had 1-2 mg estradiol (E 2 )/day in combination with norethisterone of 1 mg/day (nZ9) or medroxyprogesterone of 10 mg/day (nZ2); and three had !35 mg ethinyl E 2 /day in combination with levonorgestrel of a maximum 150 mg/day. Two women had estrogens only (1.25 mg conjugated estrogens/day) and one had only gestagens (150 mg medroxyprogesterone/3 months). One was postmenopausal and had 2 mg of E 2 together with 1 mg of norethisterone. Four women received DHEA or testosterone. The remaining three women had regular menstrual cycles.
For 18 males, 250 mg of testosterone was given by injection at 3-4 weekly intervals (nZ15), or as transdermal (nZ2), or oral therapy (nZ1). Four patients were smokers (three females).
Most (86%) of the patients were receiving GH therapy at the time of the study and only two patients with GHD had been, but were not presently, on GH therapy. Except for five patients, all had started GH therapy at a median of 13 (3-46) years of age. Duration of GH therapy was 10 (3-19) years in women and 12 years in men. Daily GH doses were 0.8 (0.4-1.6) mg in women and 0.5 (0.2-1.0) mg in men. At the time of this study, four patients (three females) did not fulfill the criteria for GHD after proper testing (15) .
Controls
Each patient was matched with a control subject, which was randomly selected from a computerized population register described elsewhere, similar in age, sex, residence (rural/non-rural), and smoking habits (16) . Among female controls, seven used oral contraceptives, all with a combination of 35 mg ethinyl E 2 and 250 mg levonorgestrel or up to 0.75 mg norethisterone, and one control was postmenopausal and without sex steroid substitution.
Ethical approval for this study was granted by Lund University Ethics Committee and written informed consent was obtained from each subject.
BMD, BMC, and anthropometric measurements
BMD and BMC at the femoral neck, L2-L4, and Z-scores at femoral neck and L2-L4 and body composition, i.e. fat and lean mass were assessed using two DXA machines (Lunar Expert XL (LEXL) and Lunar Prodigy (LP), Lunar Co., Madison, WI, USA), since the first machine broke after measurements of 27 patients and 21 controls. Both machines were calibrated with the same phantom. For BMD and BMC, the coefficient of variation (CV%) was 0.6 and 0.2%, respectively, for the LEXL and LP, and was 0.7% between machines. The conversion factors from LEXL to LP were 0.945 for fat mass and 1.018 for lean body mass (17) .
BMI was defined as body weight (kg) divided by the square of height (meters).
Biochemical assays
Blood samples were drawn in the morning after fasting since midnight and details of assay procedures for serum levels of IGF1, testosterone, leptin and plasma levels of insulin, TSH, free thyroxine (T 4 ), free triiodothyronine (T 3 ), E 2 , DHEA have been presented elsewhere (16) . Total testosterone was analyzed with the Roche Elecsys testosterone II assay on a cobas e 602 analyzer using a high-affinity sheep MAB with electrochemiluminescent detection (Roche Diagnostics). Intraassay CV was 4.2% at 0.2 nmol/l and the lower detection limit was 0.087 nmol/l. Free testosterone was calculated using the law of mass action (18, 19) . The calculation was based on the measurement of testosterone, total SHBG, and albumin.
Plasma osteocalcin was assayed by an immunometric method (Elecsys 2010). The inter-and intra-assay CV were 2.3% at 20 mg/l level and 2.4% at 200 mg/l level. Plasma levels of crossLaps were analyzed with an immunometric method (Elecsys 2010), and the interand intra-assay CV were 5.9% at 350 ng/l level and 3.7% at 3000 ng/l level.
Assessments of physical activity
Physical activity was assessed by three different measures. First, physical exercise during leisure time and work time was investigated with a self-rating questionnaire, which classified activity into a four-grade scale during winter and summer time (20) . Secondly, participants were interviewed by a dietician to describe their usual activity pattern during an ordinary 'day' and daily activities were assessed in periods of 15-min intervals as either 'active' (standing, walking, housework, and sports) or 'inactive' (sleeping, lying down, reading, sitting, and watching television). Thirdly, the average physical activity was determined from pedometer readings over a 3-day period (21) . Patients-control pairs wore their pedometer on the same weekdays.
Statistical analysis
Data are presented as median and range (max-min). Differences between patients and controls were compared using the Wilcoxon signed rank test for matched pairs. Bivariate correlations were assessed using the Spearman rank correlation coefficient. A P value !0.05 was regarded as statistically significant. In a multiple linear regression analyses, BMD was the dependent variable and leptin, free T 4 , gender, age, and weight were independent variables. SPSS for windows, version 15.0, were used.
Results
Anthropometric measurements, BMD, BMC, calcium intake and markers of bone turnover in patients compared with matched controls Height was similar in patients and controls (Table 1) . Weight, BMI, and fat mass were significantly higher in CP women only (Table 1) . Lean mass was similar in patients and controls.
At all sites studied, BMD, BMC, and Z-scores were without significant differences between CP men and controls (Table 1) . In CP women, BMD at L2-L4, and femoral neck, and Z-scores at L2-L4 were all significantly lower compared with controls (Table 1) . Nine CP women and four CP men had Z-scores %K2.0 S.D. Table 1 Anthropometric measurement, body composition (dual-energy X-ray absorptiometry), BMD, bone Z-scores, calcium intake and biochemical bone markers in 20 childhood onset craniopharyngioma women and 19 childhood onset craniopharyngioma men and matched population controls.
Women (median (range))
Men (median (range)) Six out of nine CP women and three out of four CP men with Z-scores %K2.0 S.D. had tumor growth into the third ventricle of the hypothalamus. Among these nine patients with low Z-scores and also tumor growth into the third ventricle of the hypothalamus, all but two had BMI above O30 kg/m 2 . Seven of the women with Z-score %K2.0 S.D. were between 19 and 32 years of age at the time of investigation and two were 40 years or older.
Plasma osteocalcin and crossLaps levels were significantly higher in CP male patients compared with controls, but without significant differences in CP females.
Daily calcium intake was significantly lower in CP men than in controls, but was similar in CP women and controls (Table 1) .
Hormone assessments and physical exercise in patients compared with matched controls
Serum levels of testosterone, free testosterone, and DHEA were significantly lower in CP women than in controls, but with no difference in plasma E 2 for either gender (Table 2) . Also, testosterone levels were similar in CP men compared with controls. Serum insulin levels were significantly higher in CP women, but not in CP men, compared with controls. Serum leptin was significantly higher in both CP women and men compared with controls, but only CP women had significantly higher leptin/kg fat mass. No difference was recorded in serum IGF1 levels between patients and controls of either gender. Plasma free T 4 levels were significantly higher in both gender, but free T 3 levels were lower in CP men only.
Only during winter, CP men (PZ0.02) and women (PZ0.046) were significantly less active during leisure time than controls. Inactive time was also significantly higher in CP men than in controls (PZ0.007). Pedometer readings over 3 days were significantly lower in CP men only (PZ0.05).
Correlations between disease-related factors and BMD or Z-scores
There were no significant correlations between age at surgery or tumor extension and BMD at any site (PO0.3). Time since first operation was significantly negatively correlated with BMD at femoral neck (rZK0.5, P!0.001, Fig. 1 ). Further, no significant correlation was recorded between serum insulin and BMD at any site among patients. Serum leptin correlated negatively with BMD and Z-score at L2-L4 (rZK0.5, PZ0.003), but with no significant correlation with BMD at femoral neck (PO0.1). Plasma free T 4 correlated significantly negatively with BMD at L2-L4 (rZK0.3, PZ0.04). Serum levels of crossLaps and osteocalcin were without significant correlation with BMD at any site (all PO0.3). Among females, serum E 2 or free testosterone were without significant Time since first operation (years) Figure 1 Correlation between bone mineral density (BMD) femoral neck and time since first operation (years) (rZK0.45, PZ0.004) in 39 patients with a childhood onset craniopharyngioma.
correlation with BMD (PO0.3), but in male patients, serum E 2 was significantly positively correlated with BMD at femoral neck (rZ0.6, PZ0.007, Fig. 2 ) and L2-L4 (rZ0.5, PZ0.03).
In a multiple linear regression analyses with BMD as dependent variable, neither leptin, free T 4 , gender, age, nor weight were significantly correlated with BMD (all; PO0.1).
Discussion
To the best of our knowledge, this is the first study on BMD in a group of adults with CO-CP on complete hormone replacement, including long-term GH therapy. CP females, but not CP males, had significantly lower BMD than matched population controls, despite similarities between gender in pituitary hormone deficiencies and substitution therapies. A rather remarkable finding in this study was that 45% of CP women had Z-scores %K2.0 despite numerous factors known to be positive for bone formation, e.g. increased BMI, fat mass, insulin levels, and sufficient intake of calcium, with rather adequate physical activity and none were ever smokers. Furthermore, all but two patients had passed the age of peak bone mass. In contrast, CP male patients appeared to be less affected by low BMD compared with controls, in spite of insufficient physical exercise and also lower calcium intake. Yet, levels of osteocalcin and crossLaps were significantly higher only in CP male patients, which indicate a high bone turnover and may result in a future risk of bone loss (22) .
The reduced BMD in the CP women is in accordance with a previous study showing increased fracture incidence in CO GHD women, but not in CO GHD men on long-term GH therapy (12) . Contributing factors might be late-onset puberty resulting in later than optimal introduction of sex steroids. As late-onset puberty is associated with low peak bone mass in both genders (23, 24) , it is more deleterious to the female skeleton (25) . In addition, reduced BMD has been shown after the use of oral contraceptives with an average ethinyl E 2 dose of 20-35 mg in healthy adolescents (26) . These levels were close to the estrogen doses used during adolescence among the majority of the CP women in the present study and could indicate insufficient sex steroid replacement. In addition, the lower levels of testosterone and DHEA in CP women may also contribute to the reduced BMD (27) . Low testosterone levels has been difficult to measure due to methodological problems, but new commercially available methods such as the testosterone method used in this study using a high-affinity sheep MAB has better concordance with the reference method liquid chromatography-mass spectrometry (LC-MS/MS) (28) . The testosterone levels were almost undetectable in several of our female patients giving extremely low free testosterone levels. Some data exists on postmenopausal women showing a positive correlation between bone density and testosterone levels (18) and Buchanan et al. (19) found that androgens independently predict parts of peak bone mass in normal women. However, no correlation was recorded at any sight of BMD with total or free testosterone among the female patients. One possible explanation for absent correlations could be that the testosterone levels were not normally distributed and even more suppressed by the sex steroids given.
In men, testosterone is converted to estrogen, which aids normal bone mineral accretion (29) , shown by the strong positive correlation between serum E 2 and BMD in CP men in the present study. Furthermore, the production of hepatic IGF1, which mediates the effect of GH on bone, is impaired by oral estrogens and enhanced by testosterone (30, 31) . However, this was counteracted by higher GH doses in CP women than in CP men, which resulted in similar serum IGF1 levels in patients and controls (30) . Although the exact GH replacement during childhood and adolescence is not known for the cohort, patients of both genders were of a similar height and lean mass compared with controls, suggesting rather adequate previous GH therapy.
Serum free T 4 levels were significantly increased in CO-CP patients relative to controls and there was a significantly negative correlation between free T 4 and BMD at L2-L4 in patients. However, there is presently no sufficient evidence to show that slightly higher L-T 4 replacement doses reduce BMD (32) . In addition, as L-T 4 doses and serum free T 4 levels were similar in CP men and women, it is unlikely that this replacement caused the low BMD in CP women. In addition, in the multiple linear regression analyses, no significant effect was shown by free T 4 on BMD. Glucocorticoid-induced osteoporosis is well known (33) , but long-term glucocorticoid replacement is not reported to affect BMD in hypopituitary patients (34) . The median hydrocortisone doses in CP men were supplemented as suggested, and the levels were even lower in CP women (32). Serum leptin levels were significantly increased in both CP women and men and correlated significantly negatively with BMD. Leptin resistance, shown by increased leptin/kg fat mass, was more pronounced in CP women than in men. However, three men had to be excluded from the study as they were weighing too much for the DXA machine, which may affect this conclusion. In some studies, leptin seems to have a positive effect on bone formation through a central hypothalamic action (7) , while in adolescents, a negative correlation between leptin and BMD was shown (8) . It seems reasonable to believe that the hypothalamic damage together with leptin resistance, recorded in many of the CP patients, is of paramount importance as 67% of all CP women, and 75% of the whole patient cohort with Z-scores of %K2.0 (S.D.) at L2-L4 were affected by hypothalamic damage from the tumor and the vast majority of these latter patients had also high BMI (O30 kg/m 2 ). Thus, high BMI was not protective against low BMD. The hypothalamus regulates bone and adipose tissue via a complex and fine-tuned interplay of endocrine mechanisms (of which neuropeptide Y is a key regulator) together with the sympathetic nervous system. While many of the effects occur via direct actions on osteoblasts or adipocytes, sex hormones can also mediate effects on bone and adipose tissue via interaction with neuronal pathways. Thus, both early and persistent hypothalamic dysfunction and insufficient sex hormone replacement at disease onset are likely to have attributed to the observed long-term effects on bone in these patients. In agreement, higher leptin levels were not protective, and therefore, perhaps even male patients with persistent hypothalamic dysfunction might still be at increased risk for decreased BMD later in life. Thus, the interaction between the fatrelated endocrine system and bone seems to be complex and may be modulated by central and peripheral mechanisms as well as local resistance to the putative protective effects of insulin and leptin on bone. This interrelation has been studied in diet-induced obese insulin-resistant premenopausal women versus insulin sensitive women (35) . However, patients with hypothalamic tumor involvement more often suffer from a more pronounced hypopituitarism, which makes a strong causative conclusion difficult.
We included all surviving patients operated for a CP during 42 years from a background population of 2.5 million. Based on the annual incidence of CO-CP (0.4/million person-years) (36) , the present cohort is thus representative for the entire population of CO-CP patients. However, as we included survivors, we cannot exclude that non-survivors may have exhibited a somewhat different demographic profile from our study cohort. Even if our control group represents a selected population, we consider it appropriate as a similar percentage of patients (9%) and controls (14%) declined to participate due to health reasons.
In conclusion, at a median age of 28 years, BMD was significantly reduced in CP women, despite long-term GH therapy. Contributing factors include late-onset puberty and a lack of androgen supplementation and possibly insufficient estrogen supplementation during adolescence and thereafter. Furthermore, hypothalamic involvement with leptin resistance may have contributed. Continuous surveillance of BMD is recommended in patients with a history of childhood CP and particularly among patients with a hypothalamic tumor involvement. Whether androgens and higher estrogen supplementations should be recommended in CP women needs further investigations. 
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